Teva's (NYSE:TEVA) CEO recently spoke at the JPMorgan Healthcare Conference and offered his view on the company's future. This drugmaker certainly has many future opportunities, but it's also facing the imminent patent expiration of its leading MS drug, Copaxone, a compound that currently accounts for a fifth of the company's revenue.

While Biogen (NASDAQ:BIIB) continues to steal the spotlight as its MS drug BG-12 nears an FDA decision, a discussion of the MS market was absent from the conference talk. In this video, Max Macaluso offers an overview of this presentation, compares Teva's profit margins to its generic pharma peers Watson Pharmaceuticals (NYSE:AGN) and Mylan (NASDAQ:MYL), and discusses his outlook for Teva.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.